## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Response	s)									-					
1. Name and Address of Reporting Person *- Rowinsky Eric K				2. Issuer Name <b>and</b> Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
C/O FORTREGG DIOTECH DIG 3			3. Date of Earliest Transaction (Month/Day/Year) 01/01/2017								Officer (give title below) Other (specify below)				ow)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
NEW YORK, NY 10014		_														
(City)		(State)	(Zip)			Ta	able I -	Non-Deriv	vative Secu	ıritie	s Acquire	ed, Dispose	d of, or Bei	neficially Ow	ned	
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, it any (Month/Day/Year		ate, if	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D) B			lowing	Ownership Form:	7. Nature of Indirect Beneficial Ownership	
				(Monas Buy) Tour		10)	Code V		Amount	(A) o (D)		,				(Instr. 4)
Common S	Stock, par	value \$0.001	01/01/2017				A		100,000	A	\$ 0 3	50,000			D	
(Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date, is	if Transaction Code (Instr. 8)		5. Nof Der Sec Acc (A)	wants  Number  ivative  urities  quired  or  posed	, options, c	ercisable and Date sy/Year)			nd of ng s		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form of Derivativ Security: Direct (I or Indire	)
						(Ins 4, a	str. 3, and 5)	Date Exercisabl	Expiration ble Date	on	Title	Amount or Number of		(Instr. 4)	(Instr. 4)	
Options to purchase Common Stock	\$ 6.25			Cod	e W	(A)	(D)	(2)	02/10/2	2022	Commo Stock	Shares		15,000	D	
Options to purchase Common Stock	\$ 2.10							(3)	12/19/2	2023	Commo Stock	on 30,000		30,000	D	
Report	ing O	wners					1									

Describe Common Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Rowinsky Eric K C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

## **Signatures**

/s/ S. Halle Vakani, Attorney-in-Fact	01/24/2017			
**Signature of Reporting Person	Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One-third of the shares will vest on each of January 1, 2018, 2019 and 2020, and subject to continued service on the board of directors.
- (2) One-third of the shares vested on each of February 10, 2013, 2014 and 2015.
- (3) One-third of the shares vested on each of December 19, 2014, 2015 and 2016.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see}\ Instruction\ 6 for procedure.$ 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.